NicOx Press Releases

	NicOx press releases (2007-2008)


	Archives (from 1996 up to date):
	Select a year and / or Keyword.. GO



	Title		Date

	• NicOx announces blood pressure analysis from 301 phase 3 study for naproxcinod at EULAR		13/06/2008

	• NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study		28/05/2008

	• NicOx announces departure of Damian Marron for CEO position		27/05/2008

	• NicOx reports first quarter 2008 financial results		14/05/2008

	• NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc.		13/05/2008

	• NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program		06/05/2008

	• NicOx signs agreement for the commercial manufacture of naproxcinod drug substance		19/03/2008

	• NicOx initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis		03/03/2008

	• Financial results for full year 2007: NicOx significantly advances clinical programs		03/03/2008

	• NicOx signs extension of ophthalmology agreement with Pfizer		08/01/2008

	• NicOx announces Pfizer initiates phase 2 clinical development for PF-03187207 in Japan		03/01/2008

	• NicOx completes enrollment in second pivotal phase 3 study for naproxcinod and provides development update		14/12/2007

	• NicOx announces TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020		20/11/2007

	• NicOx’ naproxcinod phase 3 results presented at American College of Rheumatology		12/11/2007

	• NicOx’ naproxcinod ABPM data presented at American Heart Association		07/11/2007

	• NicOx reports results for the first nine months of 2007		29/10/2007

	• NicOx opens US headquarters in New Jersey		15/10/2007

	• NicOx and Ferrer present promising clinical and preclinical results in dermatology		02/10/2007

	• NicOx reports TOPIGEN to advance TPI-1020 into phase 2 for COPD following promising clinical results		11/09/2007

	• First half 2007 financial results: NicOx strengthens balance sheet and advances naproxcinod		30/07/2007

	• NicOx receives €5 million milestone from Merck & Co., Inc. as drug candidate enters clinic		16/07/2007

	• NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization		02/07/2007

	• NicOx initiates third pivotal naproxcinod phase 3 study		29/06/2007

	• NicOx provides an update on NCX 4016		18/06/2007

	• NicOx provides an update on the phase 2a study for NCX 1000 conducted with Axcan		11/05/2007

	• NicOx reports first quarter 2007 financial results		11/05/2007

	• NicOx recruits Sanjiv Sharma as Vice President Commercial Affairs in the United States		30/04/2007

	• NicOx initiates second phase 3 study to confirm naproxcinod’s efficacy and improved blood pressure profile		03/04/2007

	• NicOx announces that Pfizer has disclosed further details of glaucoma trial for PF-03187207		29/03/2007

	• Clinical development initiated on lead compound in NicOx’ glaucoma collaboration with Pfizer		28/03/2007

	• NicOx’ 2006 financial results reflect a successful year of strong achievements and value creation		01/03/2007

	• NicOx announces the success of its €130 million rights issue		14/02/2007

	• NicOx presents promising pre-clinical results on an NO-donating latanoprost derivative from its glaucoma collaboration with Pfizer		12/02/2007

	• NicOx announces the terms of its rights issue to advance naproxcinod and broader pipeline		29/01/2007

	• NicOx launches a €130 million rights issue to advance naproxcinod and broader pipeline		22/01/2007

	• NicOx receives €5 million milestone payment from Merck & Co. for antihypertensive collaboration		18/01/2007



	Click here to be added to our mailing list



	Printable version



	Archives (from 1996 up to date) GO


	For more information :

	NicOx: Karl Hanks, Director of investor relations and Corporate Communications Tel. +33 (0)4 97 24 53 42 / hanks@nicox.com

	Investors in the United States - Burns McClellan : Lisa Burns / lburns@burnsmc.com Juliane Snowden / jsnowden@burnsmc.com / Tél +1 212 213 0006

	Media in the United States - FD: Jonathan Birt, Tel +1 212 850 56 34 / jbirt@fd-us.com Media in Europe - Citigate Dewe: Sylvie Berrebi, Tel +44 (0)207 282 2949 • sylvie.berrebi@cititgatedr.co.uk David Dible, •david.dible@citigatedr.co.uk